Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CbpD_pep4 is a synthetic peptide representing an immunodominant B-cell epitope derived from the **Choline-binding protein D (CbpD)** of *Streptococcus pneumoniae*. It is being investigated as a potential antigen for the development of a polysaccharide-independent, protein-based pneumococcal vaccine. CbpD is a murein hydrolase and a key virulence factor involved in pneumococcal fratricide, a process that facilitates DNA release and genetic transformation during colonization. Preclinical studies have demonstrated that immunization with CbpD_pep4, particularly when used in combination with other pneumococcal protein epitopes (such as PhtD, PhtE, and ZmpB), elicits high titers of opsonophagocytic antibodies (OPKA) and confers protective immunity against lethal challenge with virulent pneumococcal serotypes, including serotype 3, in murine models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CbpD_pep4.